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Untreated Patients Dying With AIDS
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and Glia Cells
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Bente Pakkenberg1,3*
1 Research Laboratory for Stereology and Neuroscience, Copenhagen University Hospital, Bispebjerg and Frederiksberg,
Copenhagen, Denmark, 2 Gubra, Hørsholm, Denmark, 3 Institute of Clinical Medicine, Faculty of Health and Medical
Sciences, University of Copenhagen, Copenhagen, Denmark
Untreated human immunodeficiency virus (HIV) depletes its host CD4 cells, ultimately
leading to acquired immunodeficiency syndrome (AIDS). In brain, the HIV confines
itself to astrocytes and microglia, the resident brain macrophages, but does not
infect oligodendrocytes and neurons. Nonetheless, cognitive symptoms associated with
HIV and AIDS are attributed to loss of axons and white matter damage. We used
design-based stereology to estimate the numbers of neocortical neurons and glial cells
(astrocytes, oligodendrocytes, and microglia), in a series of 12 patients dying with AIDS
before the era of retroviral treatments, and in 13 age-matched control brains. Relative to
the control material, there was a 19% loss of neocortical neuron (p = 0.04) and a 29%
reduction of oligodendrocytes (p = 0.003) in the patients with AIDS, whereas astrocyte
and microglia numbers did not differ between patients and controls. Furthermore, we
saw a 17% reduction in mean hemispheric volume in the AIDS group (p = 0.0015),
which was driven by neocortical and white matter loss (p < 0.05), while the archicortex,
subcortical gray matter, and ventricular volumes were within normal limits. Our results
confirm previous reports of neuronal loss in AIDS. The new finding of oligodendrocyte
loss supports the proposal that HIV in the brain provokes demyelination and axonal
dysfunction and suggests that remyelination treatment strategies may be beneficial to
patients suffering from HIV-associated neurocognitive deficits.
Keywords: AIDS, cerebral cortex, optical disectors, quantitative neuroanatomy, stereology
INTRODUCTION
According to The Joint United Nations Programme on human immunodeficiency virus (HIV) and
acquired immunodeficiency syndrome (AIDS) (UNAIDS, 2018), 37.9 million people globally are
living with HIV. Despite public health campaigns and effective antiviral treatments, where were
1.7 million new HIV infections recorded in 2018, and a morbidity of 7,70,000 people from AIDS-
related illnesses (UNAIDS, 2018). This reflects a halving of the incidence and morbidity since
(UNAIDS, 2018), which doubtless reflects the enormous efforts expended in disease control and
treatment. Even though forty percent of patients diagnosed with AIDS present neurological signs
or symptoms during the course of their infection, the topic of AIDS infection in the central nervous
system (CNS) is relatively neglected (Navia et al., 1986; Petito et al., 1986). Post-mortem studies
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conducted early in the epidemic found pathological CNS
alterations in 80% of patients (Navia et al., 1986; Petito et al.,
1986). Computed tomography and magnetic resonance imaging
studies indicated a progressive cerebral atrophy in AIDS, which
is linked to neuronal loss (Pedersen et al., 1991; Raininko et al.,
1992; Oster et al., 1995; Korbo et al., 2002). While atrophy is
not always attested by post mortem brain weight, morphometric
analyses performed on autopsy material from AIDS patients
indicate a 11% reduction in neocortical volume by 11 and
55% dilation of mean ventricular volume (Oster et al., 1995).
Neuronal loss may be restricted to the neocortex, since neuronal
numbers were preserved in hippocampus of AIDS patients
(Korbo and West, 2000), despite atrophy of the neuronal soma
(Sá et al., 2000).
The CNS is a major target of HIV infection (Conomy, 1989;
Glass et al., 2001), yet neuronal loss in HIV-infected patients
must be secondary to infection of microglia resident in the brain.
Furthermore, free virus particles may penetrate the CNS by
crossing the capillary endothelial cells that comprise the blood-
brain and blood-cerebrospinal fluid barriers, or be carried into
brain by infected lymphocytes or monocytes (de Almeida et al.,
2006). Once a CNS infection is established, neuronal injury
likely occurs by indirect mechanisms such as toxicity from virus
proteins, macrophage factors, cytokines, and chemokines, or due
to a loss of neurotrophic factors. While combined antiretroviral
therapy (cART) can reduce plasma viral load to undetectable
levels, it remains unclear if other HIV reservoirs persist. To
address this questions, Lamers et al. (2016) measured HIV DNA
in various autopsy tissues from a series of 20 HIV+/cART-
treated patients with low or undetectable anti mortem viral loads
and in plasma and cerebrospinal fluid (Lamers et al., 2016).
Quantitative and droplet digital PCR identified the presence of
HIV DNA in 48/87 brain tissues and 82/142 non-brain tissues
at levels exceeding 200 HIV copies/million cell equivalents. Not
one of the 20 cases was completely free of tissue HIV and
abnormal histological findings, and all examined brain tissues
demonstrated some degree of pathology, leading the authors to
propose that HIV reservoirs was present in macrophage-rich
tissues such as CNS and testis, despite complete clearance from
plasma (Lamers et al., 2016).
A stereological study of the entire neocortex from AIDS
patients dying prior to cART has previously shown a significant
decrease in the total number of neocortical neurons (Oster
et al., 1995). The individual extent of this neuron loss had
no evident relationship with the presence of clinical dementia,
HIV encephalitis or other opportunistic infections of the CNS
Given that glial changes may contribute to the AIDS-related
CNS pathology, we aimed in the present study to assess the
effect of HIV-infection on the total number of glial cells in post-
mortem neocortex from patients dying with AIDS. We undertook
this study in a unique material of brains from patients dying
before the advent of cART. Using design-based stereological
methods, we estimated the glial sub-populations, i.e., astrocytes,
oligodendrocytes and microglia, as well as neuron numbers,
in the entire neocortex of the AIDS patients comparted to
numbers in well-matched control material from patients without
neurological disease.
MATERIALS AND METHODS
The initial material included brains from 50 patients who had
died with AIDS, which had been collected consecutively from
1986 to 1989 at Hvidovre University Hospital, Copenhagen, in
accordance with Danish laws on autopsied human tissue. An
autopsy was carried out in each case, which included histological
examination of tissues from the brain and internal organs. From
among the 50 cases, we selected brains for detailed study based
on a compilation of clinical and pathological data. Excluded were
females, patients with intracranial space occupying lesions, and
history of alcohol or other drug abuse. This selection left 12
brains from AIDS patients for further examination, of whom
the six youngest patients were also included in the study by
Fischer et al. (1999), and nine had also been part of a study
by Oster et al. (1995). The duration of known HIV infection
ranged from 5–42 months, with five patients having the HIV+
diagnosis for 6 months or less and the remaining seven patients
having had the diagnosis since 2 or 3 years. Four of the AIDS
patients had subjective and/or objective signs of dementia. The
12 AIDS patients (mean age 44.6 y; range 20–67 y) were
group matched for age with the 13 control subjects (mean age
43.5 y; range 21–67 y). Table 1 shows the age, body height,
post mortem interval, cause of death, and major autopsy and
neuropathological findings in the subjects dying with AIDS. Also
shown in Table 1 are the durations of HIV infection and AIDS
diagnoses. The patient files did not indicate the precise extent of
agonal weight loss, although all AIDS patients had lost weight to
some degree and three were described as being emaciated. No
gross brain abnormalities were seen at general autopsy. Control
subjects had died from traffic accidents, homicide, or from
cardiopulmonary diseases. Their body condition was otherwise
normal, and there was no evidence of history of neurological
or psychiatric disease. The clinical data for the control subjects
are shown in Table 2. At autopsy, the brain stems were normal,
including the pigmentation of substantia nigra. There were no
tumors or neuronal glia inclusions, vasculitis or encephalitis.
Cell Characterization
We relied on morphological identification of the different cell
types, because immunohistochemical staining of specific glial
markers (e.g., glial fibrillary acidic protein, S100, and CD11b) was
not successful in all brains. The reliability of the identification
of glial subtypes (astrocytes, oligodendrocytes, and microglia)
was supported by successful immunohistochemical staining on
selected cell types. We counted cells as neurons if they contained
a single large nucleolus, in the nucleus had a typical, pale
chromatin pattern within a triangular-shaped, rounded nucleus
that was surrounded by a visible cytoplasm. Astrocytes were
defined as cells with a round, pale nucleus, heterochromatin
concentrated in granules in a rim below the nuclear membrane,
and a relatively translucent cytoplasm. Astrocytes did not always
have a small nucleolus; when present, it was most often located
eccentrically. The nuclear membrane of astrocytes had a sharp
profile and the cells were often seen as single, isolated cells
(Pelvig et al., 2008; Karlsen and Pakkenberg, 2011). On the
other hand, oligodendrocytes often occur in groups, and often
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TABLE 1 | Clinical and demographic data for AIDS patients.
# Age Body
height
(CM)
Brain
weight
(KG)
PMI
(days)
Cause of death Major autopsy
findings
Neuropathological
findings
HIV+
(months)
AIDS
(months)
1 20 170 1320 1 Kaposi sarcoma, PCP Kaposi sarcoma Edema, gliosis 30 13
2 26 173 1275 1 Pneumonia (atypical
TB), polyneuropathy
Pneumonia,
pneumo-peritonitis
Microglial nodular
encephalitis
6 5
3 32 185 1465 2 PCP; emaciation,
dementia
pneumonia Meningoencephalitis
(Cryptococcus)
26 19
4 37 183 1290 0.6 Kaposi sarcoma; PCP Kaposi sarcoma,
CMCV
CMV encephalitis 23 13
5 39 181 1280 1.3 Chronic herpes, oral
candidiasis,
emaciation, uremia
PCP Microglial nodular
encephalitis
5 1
6 40 187 1080 1 PCP, CMVP PCP, CMVP Edema, gliosis,
microinfarction
36 1
7 46 176 1670 0.7 Pleural effusion,
intestinal Kaposi
sarcoma
Kaposi sarcoma in
rectum
Edema, gliosis 5 5
8 51 170 1495 1 PCP, herpes zoster,
CMV, retinitis
CMVP Microglial nodular
encephalitis
24 17
9 52 184 1435 1 Immunoblastic ML Immunoblastic ML,
PCP, CMVP
Edema, gliosis 6
10 56 182 1450 3 Large cell ML,
emaciation, dementia
Large cell ML,
pneumonia
edema 37 1
11 57 170 1370 – PCP, syphilis, CMV,
cystitis, dementia
CMVP CMV encephalitis 42 42
12 67 168 1340 0.6 Candida esophagitis,
cryptococcosis,
dementia
PCP Edema, gliosis 6 4
Mean and 44.6 177 1373 1.2 20.5 11.0
range 20–67 168–187 1080–1670 5–42 1–42
in close proximity to neurons or blood vessels. Cells identified
as oligodendrocytes had a small round or oval nucleus with
dense chromatin, often surrounded by an artifact halo. Microglia
cells are defined by their small elongated or comma-shaped
nuclei containing dense peripheral chromatin (Pelvig et al.,
2008; Karlsen and Pakkenberg, 2011). Examples are given in
Figure 1. Using these criteria, we could assign an identification
to more than 95% of cells, and therefore omitted the remainder
from the analysis.
Estimation of the Volume of the
Neocortex and of Brain Cell Density
One cerebral hemisphere from each subject was used for
the stereological study, and the other hemisphere underwent
histopathological examination, using methods described in detail
elsewhere (Regeur et al., 1994; Oster et al., 1995; Pakkenberg and
Gundersen, 1997; Gredal et al., 2000). In brief, the hemisphere
for stereology was embedded in 6% agar and cut into 7-mm-
thick slabs. We estimated the surface area of neocortex by point
counting; an average of 247 (range 167–316) points per neocortex
were counted on the set of slabs, which resulted in a coefficient
of error (CE = SEM/mean) of 3.5% for the cortical surface area.
The hemispheric volume was calculated by multiplying the sum
of neocortical areas for all slabs by the average slab thickness of
all slabs. Starting at random, we sampled transcortical wedges
uniformly from each neocortical region, the frontal-, temporal-,
parietal and occipital lobe. Each wedge was cut into 2-mm-
wide parallel bars and systematically randomly subsampled, such
that each neocortical subregion was represented by about ten
uniformly sampled bars. After embedding the bars in LKB-
Historesin R© we cut one 35-µm-thick section from each bar, for
staining with a modified Wolbach’s Giemsa stain. Neocortex
was defined as the entire isocortex less the archicortex, which
comprised the uncus, hippocampus, the parahippocampal gyrus,
gyrus fornicatus, and the subcallosal area.
To estimate the total number of cells in each neocortical region
N(cell, reg), we multiplied the regional neocortical reference
volume, V(reg) by the regional numerical density, NV(cell/reg)
as follows: N = NV(cell/reg)× Vref for NV = 6Q/6P× vol(dis).
Here, 6Q− is the total number of cells counted in all disectors
in a region and the term v(dis) is the total volume of these
disectors, which equals the product of the area of the counting
frame times the height of the disector, times the total number
of disectors. For cell counting we used a modified BH-2
Olympus microscope equipped with an electronic microcator
[Heidenhain(C)VRZ401] with digital readout for measuring
movements in the Z-direction and a disector height of 15 µm.
The area of counting frames were 102 µm2 in the three major
lobes and 51 µm2 for the occipital lobe, and counting was
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TABLE 2 | Clinical and demographic data for control.
# Age
(years)
Body
height
(cm)
Brain
weight
(gram)
PMI
(days)
Cause of death
1 21 179 1600 2.5 Asthma
2 21 183 1485 4 Suicide
3 34 181 1230 0.3 Homicide
4 40 179 1620 2.5 Acute myocardial
infarction
5 41 174 1432 1 Cardiomyopathy
6 43 170 1150 4 Acute myocardial
infarction
7 43 176 1680 2 Acute myocardial
infarction
8 43 175 1560 1 Acute myocardial
infarction
9 44 185 1570 1 Pulmonary
embolism
10 52 162 1365 2 Acute myocardial
infarction
11 57 180 1393 1 Acute myocardial
infarction
12 60 175 1500 1 Acute myocardial
infarction
13 67 162 1330 1.5 Acute myocardial
infarction
Mean and 43.5 176 1455 1.8
range 21–67 162–185 1150–1620 0.3–4
PMI: Post-mortem interval.
performed with a ×60 oil immersion objective resulting in final
on-screen magnifications of 2525×. The upper guard zone was
set at 4 µm and the lower guard zone at 6 µm. The mean section
thickness measured in every second disector was 26 µm (range
22–28 µm). Additionally, we confirmed the uniform distribution
of neurons within the disector height by analyzing cell density
throughout the z-distribution. All sections were coded during
the process of stereological quantification. We estimated the
extent of volumetric shrinkage, SV, for each neocortical region
by comparing the volume of a 5 mm × 5 mm × 5 mm
fixed but pre-embedded tissue to the estimated volume of the
embedded and stained tissue sections of the same block after
histological processing.
Statistical Analysis
Results in the two groups were compared with an unpaired
Student’s t-test, with the level for significance set at 0.05. If the
normality test (Shapiro–Wilk) for a data set failed, we applied the
non-parametric Mann–Whitney U test. We used the Pearson’s
correlation coefficient to test for correlation between total
numbers of neurons, oligodendrocytes, astrocytes or microglia,
and disease duration.
For all data, the coefficient of variation (CV) equals the
ratio SD/mean, which we report in parentheses throughout. In
evaluating the precision of the counting estimates, the coefficient
of error (CE = SEM/mean) provides the information necessary
for determining whether the sampling is sufficiently precise
at the various levels of the sampling scheme. There were no
significant subject group differences between the CEs. The overall
mean CE was 0.093 for the final estimates of the total number
of neurons. Upon dividing the glial cells into subgroups, we
obtained a CE of 0.078 for astrocytes, 0.068 for oligodendrocytes,
and 0.26 for microglia, versus 0.056 for the complete set of
neocortical glia cells.
RESULTS
Patients With AIDS vs. Controls, Cell
Numbers
The mean number of neocortical neurons in control brains was
22.4 billion (CV = 0.18) compared with 18.2 billion (CV = 0.31)
in AIDS patients. The apparent loss of 4.3 billion neurons (19%;
t-test, p = 0.041) was significant for the neocortex as a whole
and in the parietal lobe (t-test, p = 0.03), but not for the frontal
(t-test, p = 0.09), the temporal (Mann–Whitney, p = 0.12), or
occipital lobes (t-test, p = 0.33) (Figure 2). The mean number
of neocortical oligodendrocytes was 29.4 billion (CV = 0.27)
in control brains compared with 20.9 billion (CV = 0.21) in
AIDS brains, corresponding to a loss of 8.5 billion (29%; t-test,
p = 0.003) oligodendrocytes in the neocortex as a whole, which
was likewise significant in each of the four lobes The mean
number of neocortical astrocytes was 6.6 billion (CV = 0.30)
in control subjects and 7.5 (CV = 0.25) in AIDS brains. The
difference was not statistically significant for the entire neocortex
(t-test, p = 0.30) nor for any of the four lobes alone (t-test,
p > 0.05). The mean number of neocortical microglia was 0.77
billion (CV = 1.1) in control brains compared with 0.53 billion
(CV = 0.78) in AIDS brains. The difference was not statistically
significant in any lobe (t-test, p = 0.36).
The mean glia:neuron ratio was 1.6 in control and 1.6 in AIDS
neocortices, which is not significantly different (t-test, p = 0.74).
The sum of all glia and neurons in the entire neocortex was
59.2× 109 in controls and 47.1× 109 in AIDS, with the difference
of 12.1 billion cells corresponding to 20% fewer neurons and glia
in patients than in controls (t-test, p = 0.01).
Cell Numbers and Disease Related
Measures
There was no significant correlation between months of known
HIV infection and number of neocortical neurons (Pearson’s
correlation, r = −0.27, p = 0.40) or oligodendrocytes (Pearson’s
correlation, r = −0.45, p = 0.12). There were no significant
differences between the number of neurons or oligodendrocytes
[t-test, p(neurons) = 0.88, p(oligo) = 0.48] in the four AIDS
patients with signs of dementia, when compared with the eight
AIDS patients without signs of dementia. The numbers of
neurons and oligodendrocytes did not significantly correlate in
the group of patients with AIDS (Pearson’s correlation, r = 0.46,
p = 0.13), whereas that correlation reached significance in the
control group (Pearson’s correlation, r = 0.55, p = 0.050). The
numbers of cells (neither neurons nor glia) did not significantly
correlate with age or height in patients (Pearson correlation, age
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FIGURE 1 | Different cell types in 40 µm thick sections (not all cells are in focus). Panels (a−c) from AIDS brains, panels (d,e) from control subjects. N = neurons,
A = astroglia, O = oligodendroglia, M = microglia. E = endothelial cell (not counted). Bar = 30µm.
r = 0.45, p = 0.14, height r = 0.12, p = 0.71) or controls (Pearson’s
correlation, age r = 0.12, p = 0.71, height r =−0.03, p = 0.93).
Patients With AIDS vs. Controls,
Volumes, and Cortical Thickness
The brains from AIDS patients showed several signs of atrophy,
including a 17% reduction in bilateral hemisphere volume
[AIDS = 945 cm3 (CV = 0.15), controls = 1145 cm3 (CV = 0.12);
t-test, p = 0.0015]. Among the four great lobes, the mean volumes
of the frontal- and parietal cortices were significantly reduced in
the patient group (Table 3).
The white matter volume was also reduced in patients
[AIDS = 431 cm3 (CV = 0.15), controls = 513 cm3 (CV = 0.25);
t-test, p = 0.024], while there were no significant differences
in archicortex volume [AIDS = 37.3 cm3 (CV = 0.41),
controls = 39.3 cm3 (CV = 0.22); t-test, p = 0.69], the
volume of the central gray structures [AIDS = 43.8 cm3
(CV = 0.16), controls = 51.6 cm3 (CV = 0.24); t-test, p = 0.063],
mean ventricular volume [AIDS = 21.5 cm3 (CV = 0.37),
controls = 16.0 cm3 (CV = 0.42); t-test, p = 0.071], or cortical
thickness [AIDS = 2.53 mm (CV = 0.20), controls = 2.79 mm
(CV = 0.36); t-test, p = 0.11].
No significant difference was found between the volumetric
shrinkage in the groups of AIDS brains compared to controls (t-
test, p = 0.50).
DISCUSSION
The major findings of this study are that numbers of astrocytes
and microglia were normal, but the numbers of neurons and
oligodendrocytes significantly were lower in brains from patients
dying with AIDS in the time before cART treatment. The
finding of a 19% reduction in the total number of neocortical
neurons was not unexpected, since similar attrition has been
reported in previous studies using unbiased stereological
methods (19–27%) (Ketzler et al., 1990; Oster et al., 1995) and
semi-quantitative stereological methods (Everall et al., 1991,
1993). The specific loss of the oligodendrocyte subpopulation
of all glial cells may, in part, be explained by the generally
close relationship between the numbers of oligodendroglia
and neocortical neurons, which has been observed previously
(Pelvig et al., 2008; Salvesen et al., 2017). Oligodendrocytes are
specialized cells located in the gray matter and the subcortical
white matter, which provide the myelin sheaths around axons
enabling fast saltatory conduction of neuronal action potentials.
Although there is some limited neurogenesis in the adult
brain, oligodendrocyte precursor cells continue to divide,
proliferate, and differentiate abundantly throughout life to
secure a continuous turn-over of myelination (McLaurin and
Yong, 1995). A reduction in oligodendrocyte numbers may
therefore be interpreted to indicate increased cell death or some
impairment in the proliferation, maturation, or differentiation
process of oligodendrocyte precursor cells. There is growing
evidence that HIV viral proteins are directly damaging to
oligodendrocytes (Liu et al., 2016), and that widespread
demyelination is characteristic of HIV-associated neurocognitive
disorders (Jensen et al., 2019). Because oligodendrocytes and
neurons do not express the primary receptor (CD4) permissive
for HIV-1 entry into cells, they are unlikely to host an HIV-1
infection (Bracq et al., 2018). However, viral proteins released
from infected astrocytes and microglia may be taken up by
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FIGURE 2 | Loss of neocortical neurons and oligodendrocytes in AIDS patients. Combined boxplots and strip-charts showing the stereological cell estimates for (A)
neurons, (B) oligodendrocytes, (C) astrocytes, and (D) microglia in controls and AIDS patients, for entire neocortex, and frontal, temporal, parietal, and occipital
cortices. The boxes show the mean and the 25–75th percentile range, and whiskers the range of data within 1.5 of the interquartile range. Each point represents an
estimate from an individual brain. ∗p < 0.05, ∗∗p < 0.01.
oligodendrocytes and cause damage. The best studied of these
cytotoxic viral proteins is the trans-activator of transcription
(Tat), which has indeed been detected within oligodendrocytes.
This trans-activator of gene transcription directly affects survival,
differentiation, and myelination properties of oligodendrocytes
(O’Donnell et al., 2006; Zou et al., 2015, 2019; Liu et al., 2017;
Stern et al., 2018). Further, the presence of a demyelination
marker (IgG antibodies against myelin oligodendrocyte
glycoprotein) in plasma and cerebrospinal fluid has been
associated with higher viral burden and HIV-1 associated
neurocognitive disorder (Lackner et al., 2010). This suggests that
perturbation of oligodendrocyte function, potentially leading
to net attrition, may be a primary cause of neuropathology
patients with HIV.
Microglia constitute is an important class of CNS glial cells
that perform various immune-modulatory functions in their
capacity as resident macrophages. Microglia are the major CNS
cell type productively infected by HIV-1, and most likely are a
major contributor to the neurotoxicity observed during chronic
HIV-1 infection (González-Scarano and Martín-García, 2005).
Cacci et al. (2008) have demonstrated that prolonged (72 h)
in vitro exposure to the bacterial endotoxin lipopolysaccharide
(LPS) induces differentiation of microglia from rat brain to a
potentially neuroprotective phenotype. They further investigated
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TABLE 3 | Cell numbers and volume by neocortical area.
Control AIDS
mean CV mean CV p value
Frontal Neurons 8.7 × 106 0.26 7.0 × 106 0.37 0.09
Oligodendrocytes 12.2 × 106 0.28 8.9 × 106 0.32 0.02∗
Astrocytes 2.6 × 106 0.37 3.2 × 106 0.38 0.15
Microglia 0.3 × 106 1.15 0.2 × 106 1.06 0.78
Volume, cm3 229.0 0.08 198.0 0.23 0.04∗
Temporal Neurons 5.1 × 106 0.40 4.1 × 106 0.35 0.12
Oligodendrocytes 7.0 × 106 0.37 4.7 × 106 0.26 0.02∗
Astrocytes 1.4 × 106 0.38 1.6 × 106 0.30 0.35
Microglia 0.3 × 106 1.01 0.1 × 106 0.62 0.60
Volume, cm3 121.0 0.31 108.0 0.17 0.07
Parietal Neurons 5.1 × 106 0.22 4.0 × 106 0.34 0.03∗
Oligodendrocytes 6.7 × 106 0.32 4.8 × 106 0.26 0.02∗
Astrocytes 1.5 × 106 0.33 1.5 × 106 0.25 0.96
Microglia 0.2 × 106 1.01 0.1 × 106 1.00 0.57
Volume, cm3 119.0 0.10 96.2 0.21 0.002∗∗
Occipital Neurons 3.6 × 106 0.31 3.1 × 106 0.41 0.33
Oligodendrocytes 3.8 × 106 0.38 2.6 × 106 0.25 0.01∗
Astrocytes 1.0 × 106 0.55 1.1 × 106 0.21 0.83
Microglia 0.1 × 106 1.17 0.1 × 106 0.57 0.47
Volume, cm3 55.9 0.28 45.2 0.27 0.09
Neocortex Neurons 22.4 × 106 0.19 18.2 × 106 0.31 0.04∗
Oligodendrocytes 29.6 × 106 0.30 21.0 × 106 0.24 0.003∗∗
Astrocytes 6.6 × 106 0.25 7.5 × 106 0.22 0.27
Microglia 0.9 × 106 1.24 0.5 × 106 0.77 0.81
Volume, cm3 524.9 0.16 447.4 0.09 0.002∗∗
∗p < 0.05 and ∗∗p < 0.01.
whether LPS regulated the properties of embryonic and
adult neural precursor cells differently with respect to the
“acute” phenotype acquired following a single (24 h) LPS
stimulation. Their results indicated that activated microglia
released pro-inflammatory cytokines which had a detrimental
effect on neuronal survival rate, whereas “chronic activation” of
microglia induced development of a neuroprotective phenotype
characterized by secretion of anti-inflammatory cytokines. They
further concluded that the nature, duration and strength of the
microglial response to insults are tightly regulated by inputs
both from neural cells and from components of the immune
system. Finally, according to Ponomarev (Ponomarev et al., 2011;
Chen et al., 2017), depending on the type of stimulus, microglia
can assume a pro-inflammatory/antigen-resenting activation
state or an anti-inflammatory/tissue-repairing activation state.
The importance of macrophages and microglia in HIV-1
infection is further emphasized in simian immunodeficiency
virus (SIV)-infected rhesus macaques with depletion of CD4+
T cells, in which persistence of the infection is sustained by
macrophages and microglial cells (Micci et al., 2014). Thus, HIV
has seemingly evolved to persist within the CNS in microglia,
maintain a level of viral replication that is refractory to immune
reactions and antiretroviral therapies that, in most patients,
suffice to effectively ablate viral load in the peripheral blood
(Chen et al., 2017).
Astrocytes are neuroectodermal-derived cells that form
important component of the blood–brain-barrier. They support
the function and metabolism of neurons, regulate the ionic
homeostasis in o the CNS, and modulate synaptic transmission
by the uptake of neurotransmitters. Further, they participate in
regulating immune responses in the brain. Astrocytes can support
low level replication of HIV, thus contributing to persistence
of the virus to persist in the CNS as a latent infection (Dong
and Benveniste, 2001; Albright et al., 2003; Alexaki et al., 2008;
Narasipura et al., 2012).
In our study none of the patients had been treated for their
HIV infection, having died between 1986 and 1989, before
introduction of efficient anti-retroviral treatments. All died
within 1–42 months after developing AIDS. Taken together, the
results indicate that in the early days of the AIDS epidemic this
specific group of AIDS patients was unable to sustain a normal
population of neurons and oligodendroglia. In contrast, despite
persistent infection of microglia and possibly astrocytes, these cell
populations did not suffer any significant attrition.
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Cerebral atrophy is one of the many manifestations of AIDS.
The loss of a significant number of neurons and oligodendrocytes
in the neocortex may suffice to explain the observed atrophy in
the group of patients, and may be a factor in the neurological
and cognitive symptoms seen in many AIDS patients, despite
effective cART treatment (Navia et al., 1986). Thompson et al.
(2005) have presented 3D maps of the pattern of vulnerable
cortical regions, where atrophy is linked with cognitive decline
and immune system suppression (Thompson et al., 2005).
Using high-resolution MRI brain scans, they created maps of
differential cortical gray-matter thickness in groups of AIDS
patients and healthy controls, revealing 15% thinning of primary
sensory, motor, and premotor cortices. We found that the brains
from our pre-cART AIDS patients showed atrophy marked by
reduced bilateral hemisphere volume and reduced neocortical
volume. In agreement with the Thompson study we found
region-specific volume loss within the cerebral cortex, namely
significant reductions of frontal and parietal cortical volumes,
whereas volume in temporal and occipital cortices was preserved.
Further, the white matter volume was significantly reduced, while
there were no significant changes in archicortex volume, the
volume of the central gray structures, ventricular volume or
cortical thickness. The lack of significant enlargement of the
ventricular volume and the non-significant reduction in the
cortical thickness stands in disagreement with our previous study
reporting larger ventricles and thinner cortex in brains of some of
these AIDS patients (Oster et al., 1995). However, the biological
variation in these parameters was rather high (CV = 0.20–0.42),
which should be taken into account in evaluation of results.
Among the several limitations of this study, we note the
histological criteria for differentiating the different cell types.
A more reliable separation of neurons and glia might have been
obtained through the use of sensitive and robust antibodies for
specific cell type markers, but this proved impossible in the
present material due to the long-term formalin fixation and the
poor penetration of antisera in plastic embedded tissue sections.
However, our morphological criteria for cell differentiation have
proved to be consistent in a number of previous stereological
studies (e.g., Pelvig et al., 2008; Fabricius et al., 2013), and
agreed with immunohistochemically derived populations (Hou
et al., 2012). Further, the specific immunological markers do
not always stain all of the cells in the target population due
to variable expression of the antigen (Korzhevskii et al., 2005;
Lyck et al., 2008). Strict definitions for the identification of
glial cells is strengthened by our inclusion of a comparable
control group. In addition, we note that our estimates of the
sum of neurons and all three glia cell types is invulnerable to
any uncertainty in distinguishing the various cells types; this
sum was substantially lower in the brains of the group of AIDS
patients compared with control subjects. A further limitation
arises from the present design in which cell counting in entire
brain lobes may have missed focal changes in cell populations, for
example in sensorimotor cortex, and the possibility of localized
gliosis cannot be rejected. This could explain why pathological
examination has described gliosis in several of the included AIDS
brains, despite present findings of reduced total glia cell number.
Finally, due to a low number of microglia in neocortex, we
sampled a small number of these cells compared with neurons,
oligodendrocytes, and astrocytes, resulting in higher CE values
for microglia. However, the biological variance of microglial
numbers was also high, with CVs between 0.78 and 1.1, so the
mean microglia numbers presented are still a robust indication of
the true numbers, despite the lower precision.
The major strength of the present study lies in our use
of design-based stereology. Whereas most earlier post mortem
studies applied two-dimensional morphometric and histometric
methods, resulting in 2D estimates or estimates based on size
distribution of 2D neuronal profiles, we used unbiased stereology,
which results in accurate estimation of total numbers and
volumes in 3D. Further, the brains from patients dying with
AIDS before the advent of cART treatment allows us to obtain
knowledge about the significant brain changes that occurred in
this unique archive material.
CONCLUSION
In conclusion, we find that patients dying with AIDS in the early
days of the AIDS epidemic suffered from a significant loss of
neocortical neurons and oligodendroglia, with preservation of
astrocytes and microglia numbers, despite the likely infection
of these cell populations. As HIV-associated neurocognitive
disorders remains a significant concern in patients who are
otherwise successfully treated with cART, there is a need for more
detailed understanding of how HIV infection and cART influence
the number and function of neocortical neurons and glial cells.
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